Irhythm Technologies (IRTC)
NASDAQ:IRTC
IRTC Stock Chart & Stats
$118.10
-$0.21(-0.23%)
At close: 4:00 PM EST
$118.10
-$0.21(-0.23%)
Day’s Range― - ―
52-Week Range$92.52 - $212.00
Previous CloseN/A
Volume94.23K
Average Volume (3M)661.84K
Market Cap
$3.82B
Enterprise Value$4.31B
Total Cash (Recent Filing)$583.76M
Total Debt (Recent Filing)$731.18M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Apr 30, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding32,316,760
10 Day Avg. Volume551,777
30 Day Avg. Volume661,843
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue5.77
Enterprise Value/Gross Profit8.18
Enterprise Value/Ebitda-547.95
Forecast
1Y Price Target
$210.45Price Target Upside78.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$876.06M
Bulls Say, Bears Say
Bulls Say
Competitive PositioningLongstanding investments in artificial intelligence and established scale position the company as a market leader in cardiac diagnostics, making meaningful disruption from new entrants less likely.
Financial PerformanceAchievement of GAAP profitability and free cash flow positivity signals improved financial strength and supports capacity to invest in growth while reducing reliance on external financing.
Geographic And Channel ExpansionRecord international volumes and expanding pilots with a national health procurement program, combined with growing adoption in innovative distribution channels, support additional revenue opportunities beyond core markets.
Bears Say
Guidance And Valuation PressureCompany guidance that fell short of analyst expectations, together with valuation multiple compression among peers, undermines investor confidence and could limit near-term share appreciation.
Product Launch DelaysDelay in the commercial launch of the Zio MCT product reduces near-term revenue expectations and may postpone anticipated contributions from the product pipeline.
Regulatory RiskReceipt of a civil investigative demand from the Department of Justice increases regulatory exposure and raises the possibility of fines or settlements that could damage financial results and reputation.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $92.52 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.82B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Apr 30, 2026 which is in 31 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Feb 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.159.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.66.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,316,760 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of $0.17 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went down -4.985%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$210.45 (78.20% Upside)
$210.45 (78.20% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 480.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.29%
12-Months-Change
Fundamentals
Return on Equity
-38.33%
Trailing 12-Months
Asset Growth
9.51%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$210.45
▲(78.20% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---